We’re looking forward to
@ASCO’s
#GU23, where Bicycle is presenting dose escalation results of the ongoing Phase I/II trial of BT8009, our BTCâ„¢ targeting Nectin-4. We will host a conference call on February 14 to review the data. Learn more:
bit.ly/3ivULuh